This bill limits how much health insurance premiums for Maine state employees can increase, specifically for fiscal years after June 30, 2026. Under the new rules, annual premium increases for active and retired state employees cannot exceed the Consumer Price Index plus 10%, while the Medicare Advantage prescription drug plan is excluded from this cap. The legislation also maintains earlier restrictions on premium increases for years prior to 2026, including a 1.5 percentage point limit for 2014 and 2015 and a 2010-11 funding level cap for 2012 and 2013. These changes directly affect state employees and retirees who currently receive health insurance through the state system.
This bill requires pharmacy benefits managers to allow covered individuals to pick up their prescriptions at a network pharmacy if a mail order pharmacy delays delivery by more than one day or sends the medication in unusable condition. It directly affects people enrolled in health plans that use mail order pharmacies and the pharmacy benefits managers who administer those plans. The law ensures continued access to necessary medications by providing an alternative dispensing option when mail order services fail to meet expected delivery standards or provide damaged products. This change aims to prevent treatment interruptions caused by mail order pharmacy issues without mandating specific delivery timelines for the pharmacies themselves.
This bill provides emergency funding to federally qualified health centers in Maine to help them expand retail pharmacy services in underserved areas. The legislation allocates $699,150 in fiscal year 2026, with $44,250 given to each health center plus an additional $8,850 for each additional site they operate. The funding is intended to support infrastructure that allows these centers to offer prescription drugs more directly to patients when retail pharmacy options are limited. It addresses concerns about reduced pharmacy access in rural areas and conflicting requirements from drug manufacturers under the federal 340B program. The bill takes effect immediately as an emergency measure to preserve public health and safety.
This bill amends Maine's insurance code to explicitly include the MaineCare program as a "carrier" for prescription drug benefit purposes. The change clarifies that MaineCare, which provides health coverage to low-income residents, is treated similarly to private insurance carriers under state insurance regulations. By adding MaineCare to the definition of carrier, the legislation ensures the program falls under existing insurance code provisions governing prescription drug benefits. This adjustment affects how MaineCare is classified within the state's insurance framework without altering the program's core eligibility or funding structure.
LD 697 directs Maine's Prescription Drug Affordability Board to set annual spending targets for prescription drugs purchased by state and local government health plans (excluding MaineCare), using a formula based on a 10-year average of medical care costs plus inflation, minus savings. The board must assess cost-reduction strategies, including reference-based pricing - which aligns drug prices with those in other regions - and establish a 12-member advisory council with representatives from state agencies, labor unions, and consumer groups to advise on setting targets and methods. The board will also identify public payors (state, county, and municipal health plans) likely to exceed the spending targets.
LD 1053 requires pharmacy benefit managers (PBMs) and insurance carriers in Maine to pass prescription drug rebates directly to patients at the pharmacy counter, reducing their out-of-pocket costs for specific medications. This law replaces a previous provision that allowed rebates to be retained by insurers instead of reaching patients. PBMs and carriers must annually report compliance to the Insurance Superintendent, who can impose civil penalties for noncompliance. The bill directly affects patients filling prescriptions in Maine and the entities managing drug coverage (PBMs and insurers). It ensures rebates from drug manufacturers serve to lower patient costs, not offset insurer premiums.
This bill prohibits Pharmacy Benefits Managers (PBMs) from charging "spread pricing" fees in Maine - meaning PBMs cannot charge health plans extra fees beyond the actual drug cost plus the pharmacy's dispensing fee. It requires PBMs to charge only for actual services performed, banning fees tied to drug prices, rebates, or patient costs like deductibles. PBMs must annually certify compliance to the Insurance Superintendent, with violations subject to a $1,000 civil penalty per violation. The bill directly affects PBMs operating in Maine and health plans that contract with them, aiming to increase transparency in prescription drug pricing.
Maine's LD 180 prohibits health insurance carriers and pharmacy benefits managers (PBMs) from discriminating against entities participating in the federal 340B drug pricing program or their contracted pharmacies. It bans PBMs from restricting patient pharmacy choices, imposing extra fees on 340B entities, or requiring special billing for 340B claims. The bill also mandates that PBMs reimburse pharmacies for drugs at no less than the national average drug acquisition cost (plus a Medicaid-level dispensing fee) at the time of dispensing, or the wholesale acquisition cost if the national average isn't available. Additionally, PBMs cannot reimburse pharmacies less than the amount they pay themselves or their affiliates for the same drug.
This bill requires Maine's Board of Pharmacy to create rules allowing retail pharmacies to operate remote dispensing sites in rural areas where pharmacy access is limited. It mandates that these sites must demonstrate geographic lack of adequate pharmacy services, include specifications for drug handling and remote pharmacist oversight via telehealth, and meet staffing, security, and record-keeping standards. The rules must cover storage, labeling, dispensing, and compliance with federal/state pharmacy laws before any remote site can operate. This directly affects rural communities with pharmacy deserts and retail pharmacies seeking to expand services.
This bill requires Maine health insurance companies to cover FDA-approved GLP-1 receptor agonist medications prescribed by a doctor, with out-of-pocket costs limited to $35 per 30-day prescription. It prohibits insurers from requiring prior authorization for this coverage and mandates an education campaign by the state insurance department about the medication and its health benefits. The requirements apply to all health plans issued or renewed on or after January 1, 2026. This directly affects patients prescribed these medications and insurers offering health plans in Maine.
